期刊文献+

耐多药结核分枝杆菌对喹诺酮类药物的耐药性与gyr基因突变的初步研究 被引量:5

Quinolone resistance and gyr gene mutations in multi-drug resistant of Mycobacterium tuberculosis
下载PDF
导出
摘要 目的分析耐多药结核分枝杆菌(Multiple drug-resistant tuberculosis,MDR-TB)临床分离株的gyr基因突变特点,探讨MDR-TB对喹诺酮类药物耐药产生与gyr基因突变的关系。方法采用比例法对耐多药结核临床分离菌株进行氧氟沙星的药物敏感性检测,应用DNA直接测序法检测MDR-TB的gyr基因突变情况。结果 125株MDR-TB临床分离株中,50株对喹诺酮类耐药,耐药率为40%。50株耐药菌株中,40株gyr基因发生突变:其中39株gyrA基因突变,突变率为78%,突变位点包括90,91和94位氨基酸;5株gyrB基因突变,其中4株合并gyrA基因突变,gyrB基因突变位点为500,506,534和539位氨基酸。结论 MDR-TB中的喹诺酮类药物耐药态势比较严峻,其对喹诺酮类药物耐药机制主要与gyrA基因突变有关。 In order ot analyze the characteristics of gyr gene mutations in clinical isolates from the patients with multi-drug resistant tuberculosis(MDR-TB) and the relation between MDR-TB with quinolone resistance and gyr gene mutations,the susceptibility of the MDR-TB clinical isolates to quinolones was tested by the proportion method.Gyr gene mutations of MDR-TB strains were detected by direct DNA sequencing.The results showed that there were 50 strains with quinolone resistance in 125 MDR-TB clinical isolates.The quinolone resistance rate was 40%.There were 40 with gyr mutations in 50 MDR-TB with quinolone resistance.Of 40 quinolone resistant MDR-TB with gyr mutations,39 mutated at condon 90,91 and 94 of gyrA gene with a mutation rate of 78%.For 5 gyrB mutatans,4 were associated with gyrA gene mutations.The mutation sites of gyrB were at condon 500,506,534 and 539 of gyrB gene.This study shows that the situation of MDR-TB with quinolone resistance is very serious.The mechanism of quinolone resistance in MDR-TB is mainly in connection with the mutation of gyrA gene.
出处 《中国人兽共患病学报》 CAS CSCD 北大核心 2011年第5期390-393,共4页 Chinese Journal of Zoonoses
基金 国家"十一五"重大传染病防治科技重大专项"结核病传播模式研究"(2008ZX100/03-010-02)
关键词 喹诺酮 GYRA基因 gyrB基因 耐多药结核分枝杆菌 耐药决定区 quinolone GyrA gene GyrB gene multi-drug resistant Mycobacterium tuberculosis resistant determining regions
  • 相关文献

参考文献12

  • 1Aziz M A, Wright A, Laszlo A, et al. Epidemiology of antitu berculosis drug resistance (the Global Project on Anti-Tuberculo sis Drug Resistance Surveillance) : an updated analysis[J]. Lancet, 2006, 368(9553), 2142-2154.
  • 2中华人民共和国卫生部.全国结核病耐药性基线调查报告(2007—2008年)[R].北京:人民卫生出版社.2010.
  • 3Aubry A X, Pan S, Fisher L M, et al. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity[J]. Antimicrob Agents Chemother. 2004,48(4):1281-1288.
  • 4Dauendorffer JN, Guillemin I, Aubry A, et al. Identification of mycobacterial species by PCR sequencing of quinolone resistance-determining regions of DNA gyrase genes[J]. J Clin Microbiol. 2003, 41(3) :1311-5.
  • 5World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs[S]. World Health Organization, Geneva, Switzerland, 2008.
  • 6中国防痨协会基础委员会.结核病诊断实验室检验规程[M].北京:中国教育出版社,2006.
  • 7van Embden J D, Cave M D, Crawford J T, et al. Strain identifi cation of Mycobacterium tuberculosis by DNA fingerprinting recommendations for a standardized methodology[J].J Clin Microbiol, 1993, 31 (2): 406-409.
  • 8Cambau E, Jarlier V. Resistance to quinolones in mycobacteria [J]. ResMicrobiol. 1996,147(1-2):52-59.
  • 9Mokrousov I, Otten T, Manicheva O, et al. Molecular Characterization of Ofloxaein-Resistant Mycobacterium tuberculosis Strains from Russia[J]. Antimicrobial Agents and Chemotherapy,2008, 52(8) :2937-2939.
  • 10安慧茹,王巍,李洪敏,何珂,刘真,李素梅.结核分支杆菌耐喹诺酮分子机制的研究[J].中国抗生素杂志,2005,30(2):103-106. 被引量:3

二级参考文献14

  • 1Jarlier V, Nikaido H. Permeability barrier to hydrophilic solutes in Mycobacterium chelonei [J ]. J Bacteriol, 1990,172:1418.
  • 2Takiff H E, Cimino M, Musso M C. et al. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis [J].Proc Natl Acad Sci USA. 1996.93 : 362.
  • 3Yew W W. Chan C K, Leang C C. et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong [J]. Chest, 2003,124(4): 1476.
  • 4Alangaden G J, Lerner S A. The clinical use of flouroquinolones for the treatment of Mycobacterial diseases[J]. Clin Infect Dis, 19 9 7 , 2 5 : 1213.
  • 5Richeldi L, Covi I. Ferrara G, et al. Clinical use of levofloxacin in the long-term treatment of drug resistant tuberculosis [J]. Monaldi Arch Chest Dis, 2002,57 ( 1 ) : 39.
  • 6Takiff H E, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations [J]. Antimicrob Agents Chemother, 1994, 38(4):773.
  • 7Alangaden G J, Manavathu E K, Vakulenko S B, et al.Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients [J]. Antimicrob Agents Chemother, 1995,39 (8) : 1700.
  • 8Guillemin I, Cambau E, Jarlier V. Sequences of conserved region in the a subunit of DNA gyrase from nine species of the genus Mycobacterium: phylogenetic analysis an dimplication for intrinsic susceptibility to quinolones [J].Antimicrob Agents Chemother , 1995,39 (9):2145.
  • 9Kocagoz T, Hackbarth C J, Unsal I, et al. Gyrase mutations in laboratory-selected, fluoroquinolone- resistance,mutants of Mycobacterium tuberculosis H37Ra [J ].Antimicrob Agents Chemother , 1996,40(8) : 1768.
  • 10Guillemin I, Jarlier V, Cambau E. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA Gyrase in Mycobacteria [J].Antimicrob Agents Chemother, 1998,42 (8):2084.

共引文献36

同被引文献38

  • 1安慧茹,王巍,李洪敏,梁建琴,刘真,李素梅,何珂.结核分枝杆菌耐喹诺酮临床分离株gyrA基因突变的研究[J].中国防痨杂志,2004,26(3):129-132. 被引量:3
  • 2符志军.氟喹诺酮类药物抗结核作用的评价[J].医药导报,2006,25(3):204-206. 被引量:15
  • 3胡伟,王红,程丽,周曾芬,李晓燕,段丽萍,陈娅蓉,蒋海燕,贾友兰.蒲公英对幽门螺杆菌体外抑菌作用的实验研究[J].胃肠病学,2006,11(6):365-366. 被引量:61
  • 4崔生辉,李景云,马越.细菌对氟喹诺酮类药物的耐药机制[J].中国药房,2007,18(2):148-150. 被引量:21
  • 5中国防痨协会基础专业委员会.结核病诊断实验室检验规程.北京:中国教育出版社,2006,46-51.
  • 6中华人民共和国卫生部.全国结核病耐药性基线调查报告(2007--2008年).北京:人民卫生出版社,2010:23-61.
  • 7张贺秋,赵雁林.现代结核病诊断技术[M].北京:人民卫生出版社,2013: 50-56.
  • 8Zhang Z, Lu J, Wang Y, et al. Prevalence and molecular cha-racterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob Agents Chemother, 2014,58(1):364-369.
  • 9Ginsburg AS,Grosset JH,Bishai WR.Fluoroquinolones,tuberculosis.and resistance.Lancet Infect Dis,2003,3(7):432-442.
  • 10Antonova OV, Gryadunov DA, Lapa SA, et al. Detection ofmutations in Mycobacterium tuberculosis genome determining resistance to fluoroquinolones by hybridization on biological microchips. Bull Exp Biol Med,2008,145(1):108-113.

引证文献5

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部